AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.760
+0.070 (2.60%)
Sep 11, 2026, 4:00 PM EDT - Market closed
AC Immune Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 17.51 | 3.57 | 27.31 | 14.8 | 3.94 | - | |
Revenue Growth | -39.45% | -86.92% | 84.51% | 276.14% | -74.50% | - |
Cost of Revenue | 45.91 | 56.44 | 62.57 | 54.61 | 60.34 | 62.28 |
Gross Profit | -28.41 | -52.86 | -35.26 | -39.81 | -56.4 | -62.28 |
Selling, General & Admin | 15.47 | 16.09 | 17.26 | 15.31 | 15.79 | 17.91 |
Other Operating Expenses | -0.18 | -0.09 | -0.14 | -1.49 | -1.34 | -1.18 |
Operating Expenses | 15.29 | 16 | 17.12 | 13.82 | 14.45 | 16.73 |
Operating Income | -43.7 | -68.86 | -52.38 | -53.62 | -70.85 | -79.01 |
Interest Expense | -0.21 | -0.19 | -0.13 | -0.18 | -0.36 | -0.58 |
Interest & Investment Income | 1.12 | 1.87 | 3.2 | 1.04 | 0.07 | 6.49 |
Currency Exchange Gain (Loss) | 0.09 | -2.8 | -1.6 | -1.47 | 0.39 | 0.11 |
EBT Excluding Unusual Items | -42.7 | -69.99 | -50.91 | -54.22 | -70.74 | -72.99 |
Merger & Restructuring Charges | -0.46 | -0.46 | - | - | - | - |
Pretax Income | -43.16 | -70.45 | -50.91 | -54.22 | -70.74 | -72.99 |
Income Tax Expense | - | - | 0 | 0.01 | 0.01 | 0 |
Net Income | -43.16 | -70.45 | -50.92 | -54.23 | -70.75 | -73 |
Net Income to Common | -43.16 | -70.45 | -50.92 | -54.23 | -70.75 | -73 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 101 | 101 | 100 | 85 | 84 | 75 |
Shares Outstanding (Diluted) | 101 | 101 | 100 | 85 | 84 | 75 |
Shares Change | 1.25% | 1.06% | 17.71% | 1.36% | 11.48% | 4.24% |
EPS (Basic) | -0.43 | -0.70 | -0.51 | -0.64 | -0.85 | -0.97 |
EPS (Diluted) | -0.43 | -0.70 | -0.51 | -0.64 | -0.85 | -0.97 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -51.09 | -70.16 | 65.27 | -61.21 | -74.81 | -68.32 |
Free Cash Flow Per Share | -0.50 | -0.70 | 0.66 | -0.72 | -0.90 | -0.91 |
Gross Margin | -162.23% | - | -129.12% | -268.94% | - | - |
Operating Margin | -249.58% | -1927.32% | -191.80% | -362.30% | -1800.43% | - |
Profit Margin | -246.48% | -1971.65% | -186.44% | -366.41% | -1798.04% | - |
Free Cash Flow Margin | -291.78% | -1963.67% | 238.99% | -413.55% | -1901.07% | - |
EBITDA | -42.48 | -67.47 | -50.89 | -51.95 | -69.05 | -77.11 |
EBITDA Margin | -242.61% | - | -186.36% | - | - | - |
D&A For EBITDA | 1.22 | 1.39 | 1.49 | 1.67 | 1.79 | 1.9 |
EBIT | -43.7 | -68.86 | -52.38 | -53.62 | -70.85 | -79.01 |
EBIT Margin | -249.58% | - | -191.80% | - | - | - |
Revenue as Reported | 17.51 | 3.57 | 27.31 | 14.8 | 3.94 | - |